LEDGER STEVEN A 4

What Happened Steven Ledger, Chief Executive Officer of Serina Therapeutics, was granted an award of 230,100 derivative shares (reported as an acquisition, code A) on February 3, 2026. The filing reports a price of $0.00 for the award (i.e., no cash paid shown in the Form 4). The award appears to be an equity-based grant (likely stock options or similar derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 17, 2026 (appears to be filed late relative to the 2-business-day rule).
• Amount: 230,100 derivative shares granted; reported price $0.00.
• Shares owned after transaction: not specified in the provided details.
• Footnote: Vesting schedule — 12/48ths of the award vests 12 months after the vesting commencement date, then 1/48th vests each subsequent month until fully vested (typical 4-year vesting with a 1-year cliff).
• Transaction type: A = grant/award (derivative security); not an immediate cash purchase or sale.

Context This is a grant of equity-linked compensation to the CEO that vests over time, not an immediate sale or open-market purchase. Such awards are common for executive compensation and are intended to align management incentives with shareholders; they do not by themselves indicate a buy or sell decision by the insider. Note the late filing — while tardy filings happen, delays can reduce transparency for investors.